Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks’ gestation in France in 2011: EPIPAGE-2 cohort study

Véronique Pierrat,1,2 Laetitia Marchand-Martín,1 Catherine Arnaud,3 Monique Kaminski,4 Matthieu Resche-Rigon,4 Cécile Lebeaux,1 Florence Bodeau-Livinec,1,5 Andréi S Morgan,3 François Goffinet,1,6 Stéphane Marret,7,8 Pierre-Yves Ancel,1,9 and the EPIPAGE-2 writing group

ABSTRACT
OBJECTIVES
To describe neurodevelopmental outcomes at 2 years corrected age for children born alive at 22-26, 27-31, and 32-34 weeks’ gestation in 2011, and to evaluate changes since 1997.

DESIGN
Population based cohort studies, EPIPAGE and EPIPAGE-2.

SETTING
FRANCE.

PARTICIPANTS
5567 neonates born alive in 2011 at 22-34 completed weeks’ gestation, with 4199 survivors at 2 years corrected age included in follow-up. Comparison of outcomes reported for 3334 (1997) and 2418 (2011) neonates born alive in the nine regions participating in both studies.

MAIN OUTCOME MEASURES
Survival; cerebral palsy (2000 European consensus definition); scores below threshold on the neurodevelopmental Ages and Stages Questionnaire (ASQ; at least one of five domains below threshold) if completed between 22 and 26 months corrected age, in children without cerebral palsy, blindness, or deafness; and survival without severe or moderate neuromotor or sensory disabilities (cerebral palsy with Gross Motor Function Classification System levels 2-5, unilateral or bilateral blindness or deafness). Results are given as percentage of outcome measures with 95% confidence intervals.

RESULTS
Among 5170 liveborn neonates with parental consent, survival at 2 years corrected age was 51.7% (95% confidence interval 48.6% to 54.7%) at 22-26 weeks’ gestation, 93.1% (92.1% to 94.0%) at 27-31 weeks’ gestation, and 98.6% (97.8% to 99.2%) at 32-34 weeks’ gestation. Only one infant born at 22-23 weeks survived. Data on cerebral palsy were available for 3599 infants (81.0% of the eligible population). The overall rate of cerebral palsy at 24-26, 27-31, and 32-34 weeks’ gestation was 6.9% (4.7% to 9.6%), 4.3% (3.5% to 5.2%), and 1.0% (0.5% to 1.9%), respectively. Responses to the ASQ were analysed for 2506 children (56.6% of the eligible population). The proportion of children with an ASQ result below threshold at 24-26, 27-31, and 32-34 weeks’ gestation were 50.2% (44.5% to 55.8%), 40.7% (38.3% to 43.2%), and 36.2% (32.4% to 40.1%), respectively. Survival without severe or moderate neuromotor or sensory disabilities among live births increased between 1997 and 2011, from 45.5% (39.2% to 51.8%) to 62.3% (57.1% to 67.5%) at 25-26 weeks’ gestation, but no change was observed at 22-24 weeks’ gestation. At 32-34 weeks’ gestation, there was a non-statistically significant increase in survival without severe or moderate neuromotor or sensory disabilities (P=0.61), but the proportion of survivors with cerebral palsy declined (P=0.01).

CONCLUSIONS
In this large cohort of preterm infants, rates of survival and survival without severe or moderate neuromotor or sensory disabilities have increased during the past two decades, but these children remain at high risk of developmental delay.

Introduction
Survival of preterm babies has increased worldwide, with a concomitant decrease in severe neonatal morbidity.1-4 However, the risk of neurodevelopmental and behavioural disabilities remains high in children5-10 and in adults who were born preterm.11 12 At extremely low gestations, ethical questions are crucial, and most recent national cohort studies have focused exclusively on extremely preterm birth.5 6 8 13-15 Controversies over treatment decisions are described.16 During the past two decades, countries with active perinatal care at extremely low gestation (eg, USA,15 England,5 Sweden,9) have reported improvements in...
outcomes for periviable infants (infants born at 22-25 weeks’ gestation). Despite these improvements, survival without neurodevelopmental impairment at 2-2.5 years was 20% in the USA for infants born at 22-24 weeks’ gestation, and 34% and 42% in England and Sweden, respectively, for infants born at 22-26 weeks’ gestation. Results from countries without recommendations for active perinatal care at extremely low gestation have been less frequently reported. In absolute numbers, infants born very and moderately preterm represent a larger proportion of preterm births accounting for more children with motor, cognitive, or behavioural deficits and learning disabilities. These populations of very and moderately preterm neonates have been poorly investigated, but knowledge of specific developmental domains affected at preschool age could lead to targeted intervention and prevention of later disabilities, as timely intervention has a positive influence on cognitive outcome in infancy. Updated information is therefore needed on outcomes for infants born at different gestational ages and in different settings to guide health policy, advise doctors in perinatal management, provide comprehensive information to facilitate parents’ involvement in shared decision making, and benchmark outcomes.

Developmental delay rather than survival is now recognised as the main problem in children born preterm. Early identification of children at risk of later developmental difficulties may increase access to formal evaluation and subsequent intervention, potentially influencing the course of otherwise persistent difficulties. The Bayley Scales of Infant Development is usually the assessment of choice for neurodevelopmental evaluation between 18 and 30 months. However, it is costly and time consuming, requires trained staff, and cannot be applied routinely to all children born preterm, particularly at more than 32 weeks’ gestation where numbers are much greater. Alternative tools that can effectively screen for developmental delay are therefore needed. Parental questionnaires are increasingly popular to assess development, as they are easy to administer and interpret, have a short completion time, and can decrease medical expenditure. In addition, they may be used in the community, have the capacity to facilitate parental involvement, and enable clinicians to focus on those children suspected of having developmental delay and hence needing further developmental assessment. The Ages and Stages Questionnaire (ASQ) is the most commonly used parent completed developmental screening test worldwide, and it is accepted by the American Academy of Paediatrics as a valid developmental screening tool; it has been translated to, and validated in, French; and there are arguments to support the cross cultural validity of the ASQ for other European countries. It could thus be useful for both large cohort studies and routine follow-up as a first step approach to increase early detection of neurodevelopmental delay. However, its use in a national population of preterm children has never been evaluated.

The 2011 EPIPAGE-2 study is a national cohort study, designed to investigate outcomes and their changes over the past 15 years for children born from 22-34 weeks’ gestation. In the original EPIPAGE cohort, data were collected on all very preterm births in nine French regions during 1997 and the surviving children were assessed at age 5 and 8 years. The original EPIPAGE cohort data were pre-coded to minimise the risk of ambiguous coding in perinatal management, provide comprehensive information to facilitate parents’ involvement in shared decision making, and benchmark outcomes.

Methods

Study design and population

EPIPAGE-2 is a prospective national population based cohort scheduled to follow preterm children up to the age of 12 years. Infants born at 22-34 completed weeks’ gestation in all maternity units in 25 French regions (21 of the 22 metropolitan regions and all four overseas regions) were eligible for inclusion. The only region that did not participate accounted for 2% of births in France in 2011. Recruitment took place at birth and children were included in the study and data collected only after families had received information and agreed to participate in the study. Hence, for children whose parents declined participation, only status at birth, mortality, and limited perinatal data were available. The study began on 28 March 2011. Infants born at 22-26 weeks’ gestation were recruited during an eight month period, those born at 27-31 weeks’ gestation during a six month period, and those born at 32-34 weeks’ gestation during a five week period. All survivors were enrolled for longitudinal follow-up and included in the study at 2 years corrected age if parents consented.

Data collection and evaluation methods

Data for children at 2 years corrected age were collected by using two standardised questionnaires: one completed by the referring doctor and the other by the parents.

Cerebral palsy and sensory deficits

We extracted data for cerebral palsy from the medical questionnaire, including information on major developmental steps (head control, sitting, standing, walking, and quality of gait), trunk and limb tone (low, normal, increased), and other abnormal neurological signs (see web appendix 1). Questions were pre-coded to minimise the risk of ambiguous answers. Questionnaires were similar in 1997 and 2011 to facilitate comparisons. Cerebral palsy was
defined according to the diagnostic criteria of the Surveillance of Cerebral Palsy in Europe (SCPE) network, and motor ability was graded by using the five level Gross Motor Function Classification System (GMFCS). We also report the proportion of children with ambulatory cerebral palsy, defined as those with cerebral palsy who were walking at 2 years of age, with or without aids. Paediatricians in charge of routine follow-up performed the examinations. If a routine follow-up was unavailable, parents were asked to get their practitioner of choice to complete the medical questionnaire to ensure higher follow-up rates. Three of the authors (VP, FBL, and SM) separately reviewed ambiguous cases, with agreement on discrepancies reached in a consensus meeting. Data on vision and hearing were obtained from medical reports available during the medical examination. In cases of blindness, visual impairment was classified as severe (bilateral) or moderate (unilateral). Squinting or the need for glasses was also recorded. In cases of deafness, auditory impairment was classified as severe (bilateral) or moderate (unilateral). Severe neuromotor or sensory disabilities included any of GMFCS level 3-5 cerebral palsy or severe visual or auditory impairment; moderate disability included GMFCS level 2 cerebral palsy with or without moderate visual or auditory impairment. Children without severe or moderate neuromotor or sensory disabilities were classified as having no or minor neuromotor or sensory disabilities.

Overall neurodevelopment
The child’s development was assessed with the second version of the 24 month Ages and Stages Questionnaire (ASQ) validated in France and completed by parents; data were analysed if completed between 22 and 26 months corrected age in children without cerebral palsy, deafness, blindness, or severe congenital brain malformations. Each questionnaire includes 30 items covering five developmental domains: communication abilities, gross motor skills, fine motor skills, problem solving abilities, and personal-social skills. Items are scored on a three point scale depending on whether the child performs the task: yes (10 points), sometimes (5 points), or not yet (0 points). Responses are summed to give a score of 0 to 60 for each domain and an overall maximum ASQ score of 300 points. Analyses were based on domain specific scores, using established screening cut-off points: an ASQ score below threshold was defined as a score lower than 2 standard deviations from the mean on any of the five domains. We also report the number and nature of domains with scores below threshold.

Other major disabilities at 2 years corrected age
Major disabilities affecting respiratory or gastrointestinal systems were recorded. Respiratory disability was defined as the need for continuous respiratory support or oxygen and gastrointestinal disability as the need for parenteral nutrition or enteral feeding through a nasogastric tube or gastrostomy, or both.

Comparison of 1997 and 2011 EPIPAGE cohorts
Children eligible for comparison were those born alive at 22-34 weeks’ gestation from the 1997 and 2011 cohorts in the nine regions participating in both studies. Outcome measures at 2 years corrected age were rates of survival, survival without severe or moderate neuromotor or sensory disabilities among live births, and cerebral palsy among survivors.

Data management and statistics
Results among live births and at 2 years are presented by gestational age grouping (22-26, 27-31, combined 22-31, and 32-34 weeks’ gestation for survival analyses; 24-26, 27-31, combined 24-31, and 32-34 weeks’ gestation for disability analyses), and by week for those born at 22-26 weeks’ gestation. Firstly, summary data on maternal characteristics (maternal age, birth outside of France, and parents’ socioeconomic status), obstetric (multiple pregnancy, antenatal steroids, and caesarean section), and neonatal factors (sex, small for gestational age, inborn status, surfactant, postnatal steroids, severe neonatal morbidities, and breast milk at discharge) are presented for children whose parents gave consent at birth and for survivors included in the study at 2 years corrected age; data were compared with those who did not participate in the initial study or were lost to follow-up. Socioeconomic status was defined as the highest occupational status of the mother and father, or mother only if a single parent, small for gestational age as birth weight <10th centile for gestational age and sex based on French “EPope” intrauterine growth curves, and severe neonatal morbidities as severe bronchopulmonary dysplasia, necrotising enterocolitis (Bell stages 2-3), severe retinopathy of prematurity stage >3, or any of the following severe cerebral abnormalities on cranial ultrasonography: intraventricular haemorrhage grade III or IV or cystic periventricular leukomalacia. Secondly, for children examined at 2 years corrected age, percentages of cerebral palsy, visual and hearing impairments, and ASQ below threshold are presented. Thirdly, among live births, rates of total survival are reported for all cases, and survival without severe or moderate neuromotor and sensory disabilities for all cases after multiple imputation to account for selective dropouts and missing information at 2 years corrected age; among survivors, rates are reported for both complete cases and all cases after multiple imputation. Multiple imputation was performed as a sensitivity analysis. Missing data were imputed by chained equations using the SAS “MI” procedure. Imputation model variables included both those potentially predicting non-response and/or outcomes (gestational age, maternal age and country of birth, parity, parental socioeconomic status, antenatal steroids, caesarean section, multiple pregnancy, sex, small for gestational age, severe congenital brain malformation, inborn status, surfactant, postnatal steroids, severe neonatal morbidities, use of breast milk at discharge), and outcomes (cerebral palsy, neuromotor or sensory disabilities, and ASQ).
ASQ, missing domains (defined as binary variables (yes/no) for a score below threshold in each of the five domains) were separately imputed to account for partially completed questionnaires. Overall ASQ score was then estimated using the domain specific imputed datasets for infants without cerebral palsy, deafness, blindness, or severe congenital anomalies. Socioeconomic data were imputed using multinomial models. Other variables with missing data, all binary, were imputed using logistic regression. We generated 50 independent imputed datasets with 30 iterations each. Estimates were pooled according to Rubin’s rule. Further details are available in web appendix 2. Fourthly, to document trends over time, we compared 1997 and 2011 rates of survival, survival without severe or moderate neuromotor or sensory disabilities among live births, and cerebral palsy among survivors and calculated the difference between 1997 and 2011 adjusted for baseline factors that may influence outcomes (gestational age, sex, small for gestational age, birth weight for gestational age, multiple pregnancy status). Risk differences were estimated using a binomial model with identity link. Cohort data were obtained from the entire year in 1997 and from 28 March 2011 to 31 December 2011. Analyses for 1997 were run for the entire year and then separately for April to December. Results did not differ, and thus 1997 data are presented for the whole year. To better understand the link between the evolution of outcomes and variations in practice, we compared the maternal characteristics and obstetric and neonatal factors of the 1997 and 2011 populations. Finally, factors associated with cerebral palsy or an ASQ score below threshold were studied for complete cases by using multiple logistic regression models. Variables entered into the models were gestational age, sex, single or multiple pregnancy status, small for gestational age, and parental socioeconomic status.

Percentages are given with their exact 95% binomial confidence intervals, and medians with interquartile ranges. For analyses performed on the overall cohort, we used weighted percentages and gestational age adjustments in the multivariable analyses to account for differences in sampling times between gestational age groups. We compared groups of infants using the χ² test. All tests were two sided; P < 0.05 was considered statistically significant. Statistical analyses were performed using SAS v9.4 software.

**Patient involvement**

Patients were not involved in setting the research question or the outcome measures, nor were they involved in developing plans for design of the study. Parents showed overwhelming support for the study through high follow-up rates and by providing testimonials (displayed on the EPiPAGE-2 website at http://epipage2.inserm.fr/index.php/fr/cote-parents/temoignages). EPiPAGE-2 maintains contact with parents in the cohort through letters, newsletters, and its website. National parents’ associations assisted with the dissemination of the results.

**Results**

EPiPAGE-2: neurodevelopmental outcomes and overall survival at 2 years corrected age

**Population**

Parental consent was obtained for inclusion of 5170 of 5567 liveborn babies between 22 and 34 weeks' gestation in the EPipage-2 study. All survivors (n = 4467) were enrolled for longitudinal follow-up; 24 died post-discharge and the parents of 244 declined further participation. Thus, 4199 children were included in the follow-up study. Among these 4199 children, medical questionnaires were available for 3600 (81.0% of all children) and parental questionnaires for 3689 (83.0% of all children) (fig 1). Overall, 148 neonates were born alive at 22-23 weeks’ gestation and all but one died in the neonatal period. This survivor was born at 23 weeks’ gestation and six days and was therefore included with those born at 24 weeks’ gestation.

Web appendix 3 shows the comparisons between children with and without parental consent at birth for participation, as well as children with and without cerebral palsy or ASQ data available.

---

**Liveborn infants at 22-34 completed weeks’ gestation (n=5567)**

- Parents refused participation (n=397)
- Excluded (n=701):
  - Died in delivery room (n=290)
  - Died in neonatal intensive care unit (n=413)
- Discharged home alive and eligible for follow-up* (n=4467)
- Survivors at 2 years eligible for follow-up (n=4443)
- Follow-up refused by parents (n=244)
- Survivors at 2 years included in follow-up† (n=4199)

**Medical questionnaire at 2 years corrected age (n=3600; 81.0%)**

- Cerebral palsy data available (n=3599; 81.0%)
- Hearing data available (n=3517; 79.2%)
- Vision data available (n=3400; 76.5%)

**Parental questionnaire at 2 years corrected age (n=3689; 83.0%)**

- Excluded (n=1052):
  - ASQ not completed (n=279)
  - ASQ completed outside the expected age (n=773)
- ASQ completed between 22 and 26 months’ corrected age (n=2637; 59.4%)
- Cerebral palsy, deafness, blindness, or severe congenital brain malformations (n=1311)
- ASQ data used in analysis (n=2506; 56.4%)

---

**Fig 1** Flowchart of study population: EPipage-2 cohort at 2 years corrected age.

ASQ=Ages and Stages Questionnaire. Percentages in parentheses are number of events/number of survivors at 2 years eligible for the study (n=4443). *No survivors at 22 weeks and only one survivor at 23 weeks and six days. 10 of the 4199 survivors at 2 years included in follow-up, 2545 had data available for both cerebral palsy and ASQ between 22 and 26 months corrected age, cerebral palsy data only were available for 1054, ASQ data only for 92, and no data were available for 508 children.
Neonates whose parents refused participation were born more frequently at 32-34 weeks’ gestation and to mothers of lower socioeconomic status. Compared with responders, children with unavailable cerebral palsy or ASQ data were more frequently born at 32-34 weeks’ gestation, after a singleton pregnancy, to younger mothers, mothers born outside France, or to mothers of a lower socioeconomic status, and were less frequently fed breast milk at discharge; however, the main neonatal outcomes did not differ between groups. Web appendix 4 shows the characteristics of children with data about cerebral palsy status according to gestational age group.

Cerebral palsy and sensory outcomes
Medical examinations were performed at a median of 24.2 months corrected age (interquartile range 23.1-25.7) and by a paediatrician in 88.0%, 80.2%, and 78.8% of children born at 24-26, 27-31, and 32-34 weeks’ gestation, respectively. Information on cerebral palsy was available from 3599/3600 questionnaires (2714 and 885 for children born at 24-31 and 32-34 weeks’ gestation, respectively). Cerebral palsy was diagnosed in 137 children: bilateral spastic cerebral palsy in 120 (weighted %, 82.3%), unilateral spastic cerebral palsy in 15 (weighted %, 16.5%), and dyskinetic or unclassifiable cerebral palsy in 2 (weighted %, 1.2%). The overall rate of cerebral palsy was 4.6% at 24-31 weeks’ gestation, decreasing from 6.9% to 4.3% between 24-26 and 27-31 weeks’ gestation. At 32-34 weeks’ gestation, the cerebral palsy rate was 1.0% (table 1). Among those with cerebral palsy, 15/31 (48.4%), 51/97 (52.6%), and 7/9 (77.8%) at 24-26, 27-31, and 32-34 weeks’ gestation, respectively, were ambulatory forms of cerebral palsy. Severe auditory or visual impairment was reported in fewer than 1% of children included in the cohort. The proportion of children wearing glasses decreased with increasing gestational age.

Neurodevelopmental outcome
Parental questionnaires were collected at a median of 24.3 months corrected age (interquartile range 23.5-26.3). Among the 3689 parental questionnaires available, ASQ analysis was possible for 2637 children (59.4% of all children). In total, 131 questionnaires were excluded because of cerebral palsy, deafness or blindness (n=121), or severe congenital brain malformations (n=10), leaving 2506 questionnaires in the complete case analysis (1884 and 622 for children born at 24-31 and 32-34 weeks’ gestation, respectively). Median ASQ scores increased from 223 at 24-26 weeks’ gestation to 235 at 32-34 weeks’ gestation (table 1). An ASQ score below threshold was observed in 50.2%, 40.7%, and 36.2% of children born at 24-26, 27-31, and 32-34 weeks’ gestation, respectively; 7.7%, 3.8%, and 1.8% of these respective groups had a score below threshold in 4-5 ASQ domains. Web appendix 8 shows the median total scores by number of domains below threshold. The domains most frequently scoring below threshold were communication and personal-social in all gestational age groups. Proportions of children scoring below the threshold in either of these domains decreased with increasing gestational age but were still 17.8% and 13.3%, respectively, at 32-34 weeks’ gestation. Although children with cerebral palsy were excluded, 16.6% of children born at 24-26 weeks’ gestation scored below the threshold in the gross motor domain compared with 5.1% at 32-34 weeks’ gestation.

Other major disabilities
Nine children out of 2667 with available data born at 24 to 31 weeks’ gestation (0.3%, 95% confidence interval 0.1% to 0.6%) still needed oxygen at 2 years corrected age, 28 of 2660 (1.0%, 0.6% to 1.4%) received enteral nutrition by tube or gastrostomy, and 3 out of 2652 (0.1%, 0.0% to 0.3%) received parenteral nutrition. The proportion of children fed by tube or gastrostomy was 2.7% (1.4% to 4.7%) at 24-26 weeks’ gestation (12/447) and 0.7% (0.4 to 1.2) at 27-31 weeks’ gestation (16/2218). Overall, 11 children out of 2470 with data available for all variables (0.4%, 0.2% to 0.7%) had respiratory or gastrointestinal disabilities associated with cerebral palsy and/or deafness or blindness. Fewer than 0.5% of children born at 32-34 weeks’ gestation (4/885) had respiratory or gastrointestinal disabilities.

Overall survival at 2 years corrected age and dropout analyses
Among live births, survival at 2 years corrected age increased with increasing gestational age and, after multiple imputation, survival without severe or moderate neuromotor and sensory disabilities was 48.5%, 90.0%, and 97.5% at 22-26, 27-31, and 32-34 weeks’ gestation, respectively (table 2). Among survivors at 2 years corrected age, rates of cerebral palsy were only slightly modified after multiple imputation, but rates of ASQ scores below threshold increased in all gestational age groups after multiple imputation. Web appendix 5 presents the outcomes for children born at 24-26 weeks’ gestation by gestational week.

Comparison of the 1997 and 2011 EPIPAGE cohorts (nine regions)
Neonates born alive at 22-34 weeks’ gestation in the nine regions participating in both EPIPAGE studies totalled 3334 in 1997 and 2418 in 2011; 2262 (1997) and 1696 (2011) were alive at 2 years corrected age with outcome data available (table 3). Follow-up rates at 2 years were 79.0% in 1997 and 82.2% in 2011. No infant born at 22-23 weeks’ gestation survived in these nine regions in either period. After adjustment for baseline characteristics, for children born at 22-31 weeks’ gestation, survival increased by 6.0% (95% confidence interval, 3.5% to 8.5%), and survival without neuromotor or sensory impairment by 7.2% (4.7% to 9.8%); in children born at 24-31 weeks’ gestation, cerebral palsy decreased by 3.3% (1.6% to 5.0%). Changes between the two periods for...
both survival, survival without neuromotor or sensory disabilities, and rates of cerebral palsy in survivors were not statistically significant for children born at 24 weeks’ gestation, but noticeable improvements were seen at 25-26 weeks and, to a lesser extent, at 27-31 weeks. Web appendix 6 presents the data for survival and survival without neuromotor or sensory disabilities by gestational weeks. At 32-34 weeks’ gestation, the rate of cerebral palsy declined by 3.3% (0.7% to 5.9%), but survival and survival without severe neuromotor or sensory impairment were similar.

Table 4 shows the changes between 1997 and 2011 in maternal characteristics and obstetric and neonatal factors. In 2011, mothers were older and parents were
For each domain, a score lower than 2 standard deviations from the mean, using established screening cut-off points (Squire 2009) was reported. If a score was below threshold in at least one domain, the disability status was unknown, and consequently only multiple imputation analysis was possible.

‡ All but one neonate born at 22-23 weeks died.

* No missing data for survival at 2 years.

Total percentages are weighted to account for differences in sampling process between gestational age groups. Data are presented by gestational age grouping: 22-26 and 27-31 (both combined, 22-31, and 32-34 weeks’ gestation).

‡ Complete cases analysis. No survivors at 22-23 weeks in the nine regions participating in both EPIPAGE studies.

† Adjusted for gestational age, sex, small for gestational age, and multiple pregnancy.

Table 2 | Survival, rates of cerebral palsy, and Ages and Stages Questionnaire (ASQ) scores below threshold at 2 years corrected age among complete cases and after multiple imputation by gestational age groups

<table>
<thead>
<tr>
<th>Variables</th>
<th>Data analysis</th>
<th>% (95% CI)</th>
<th>22-31 weeks</th>
<th>22-26 weeks</th>
<th>27-31 weeks</th>
<th>32-34 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live births</td>
<td>Survival at 2 years corrected age*</td>
<td>Complete cases</td>
<td>86.3 (83.2 to 85.4)</td>
<td>51.7 (48.6 to 54.7)</td>
<td>93.1 (92.1 to 94.0)</td>
<td>98.6 (97.8 to 99.2)</td>
</tr>
<tr>
<td></td>
<td>Survival without neuromotor or sensory disabilities at 2 years corrected age†</td>
<td>Multiple imputation</td>
<td>81.2 (79.9 to 82.4)</td>
<td>48.5 (45.4 to 51.6)</td>
<td>90.0 (88.8 to 91.1)</td>
<td>97.5 (96.4 to 98.5)</td>
</tr>
<tr>
<td>Survivors at 2 years corrected age</td>
<td>Cerebral palsy</td>
<td>Complete cases</td>
<td>4.6 (3.9 to 5.5)</td>
<td>6.9 (4.7 to 9.6)</td>
<td>4.3 (3.5 to 5.2)</td>
<td>1.0 (0.5 to 1.9)</td>
</tr>
<tr>
<td></td>
<td>Multiple imputation</td>
<td>4.8 (5.0 to 5.6)</td>
<td>7.2 (4.9 to 9.6)</td>
<td>4.6 (3.6 to 5.3)</td>
<td>1.1 (0.4 to 1.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ASQ score below threshold§</td>
<td>Multiple imputation</td>
<td>42.0 (39.7 to 44.2)</td>
<td>50.2 (44.5 to 55.8)</td>
<td>40.7 (38.3 to 43.2)</td>
<td>36.2 (32.4 to 40.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>47.8 (45.5 to 50.2)</td>
<td>55.8 (50.8 to 60.9)</td>
<td>46.7 (44.2 to 49.2)</td>
<td>42.7 (38.7 to 46.7)</td>
</tr>
</tbody>
</table>

Total percentages are weighted to account for differences in sampling process between gestational age groups. Data are presented by gestational age grouping: 22-26 and 27-31 (both combined, 23-31, and 32-34 weeks’ gestation).

‡ Severe or moderate neuromotor or sensory disability: severe=cerebral palsy GMFCS levels 3-5 and/or bilateral deafness and/or bilateral blindness; moderate=cerebral palsy GMFCS level 2 and/or unilateral deafness and/or unilateral blindness. Seven infants had associated severe or moderate cerebral palsy and sensory disabilities. For some surviving children who were lost to follow-up, the disability status was unknown, and consequently only multiple imputation analysis was possible.

*No missing data for survival at 2 years.

† IAB but one neonate born at 22-23 weeks died.

§ For each domain, a score lower than 2 standard deviations from the mean, using established screening cut-off points (Squire 2009) was reported. If a score was below threshold in at least one domain, the global ASQ was considered below threshold. Infants with cerebral palsy, deafness, blindness, or severe congenital anomalies were excluded (n=131).

Table 3 | Outcomes for children included in the nine regions participating in EPIPAGE (1997) and EPIPAGE-2 (2011) studies by weeks’ gestational age (GA)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>1997</th>
<th>2011 (EPIPAGE-1 regions)</th>
<th>% difference 2011 v 1997* (95% CI)</th>
<th>P value</th>
<th>% adjusted difference 2011 v 1997† (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live births</td>
<td>Survival at 2 years corrected age (weeks’ GA):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22-31</td>
<td>1690/2123</td>
<td>79.4 (77.5 to 81.2)</td>
<td>84.1 (82.4 to 85.8)</td>
<td>4.8 (2.6 to 6.9)</td>
<td>&lt;0.001</td>
<td>6.0 (3.5 to 8.5)</td>
</tr>
<tr>
<td>22-23</td>
<td>531/676</td>
<td>0.0 (NA)</td>
<td>0.0</td>
<td>-</td>
<td>-</td>
<td>0.0</td>
</tr>
<tr>
<td>24</td>
<td>13/42</td>
<td>32.7 (18.5 to 49.7)</td>
<td>29.2 (20.3 to 39.3)</td>
<td>-3.5 (-19.2 to 12.1)</td>
<td>0.66</td>
<td>-8.6 (-17.0 to 15.8)</td>
</tr>
<tr>
<td>25-26</td>
<td>147/177</td>
<td>53.2 (46.8 to 59.5)</td>
<td>66.6 (61.3 to 71.5)</td>
<td>13.4 (6.2 to 20.6)</td>
<td>&lt;0.001</td>
<td>12.1 (4.9 to 19.2)</td>
</tr>
<tr>
<td>27-31</td>
<td>150/1758</td>
<td>86.8 (85.0 to 88.4)</td>
<td>94.0 (92.6 to 95.2)</td>
<td>7.2 (5.4 to 9.0)</td>
<td>&lt;0.001</td>
<td>7.0 (5.3 to 8.8)</td>
</tr>
<tr>
<td>32-34</td>
<td>117/1211</td>
<td>97.2 (95.6 to 98.3)</td>
<td>97.7 (96.0 to 98.8)</td>
<td>0.5 (-0.2 to 1.2)</td>
<td>0.17</td>
<td>0.0 (-0.9 to 0.8)</td>
</tr>
<tr>
<td>Survival without neuromotor or sensory disabilities at 2 years corrected age (weeks’ GA):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22-31</td>
<td>74.5 (72.5 to 76.5)</td>
<td>80.5 (78.7 to 82.3)</td>
<td>6.1 (3.7 to 8.5)</td>
<td>&lt;0.001</td>
<td>7.2 (4.7 to 9.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>22-23</td>
<td>0.0 (NA)</td>
<td>0.0</td>
<td>-</td>
<td>0.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>29.0 (12.3 to 45.7)</td>
<td>25.8 (16.9 to 34.6)</td>
<td>-3.2 (-20.3 to 13.8)</td>
<td>0.71</td>
<td>-1.9 (-18.9 to 15.2)</td>
<td>0.83</td>
</tr>
<tr>
<td>25-26</td>
<td>45.5 (39.2 to 51.8)</td>
<td>62.3 (57.1 to 67.5)</td>
<td>16.8 (3.8 to 9.4)</td>
<td>&lt;0.001</td>
<td>17.6 (10.2 to 24.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>27-31</td>
<td>82.1 (80.2 to 84.1)</td>
<td>90.3 (88.7 to 92.0)</td>
<td>8.2 (6.0 to 10.4)</td>
<td>&lt;0.001</td>
<td>6.4 (1.1 to 4.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>32-34</td>
<td>95.7 (94.1 to 97.4)</td>
<td>96.8 (95.2 to 98.1)</td>
<td>-1.3 (-0.2 to 2.2)</td>
<td>0.095</td>
<td>0.4 (-1.2 to 2.1)</td>
<td>0.61</td>
</tr>
<tr>
<td>Survivors at 2 years corrected age</td>
<td>Cerebral palsy (weeks’ GA):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24-31</td>
<td>129/1415</td>
<td>9.0 (7.5 to 10.6)</td>
<td>5.4 (4.2 to 6.8)</td>
<td>-3.6 (-5.3 to -1.8)</td>
<td>&lt;0.001</td>
<td>-3.3 (-5.0 to -1.6)</td>
</tr>
<tr>
<td>24</td>
<td>71/111</td>
<td>7.1 (0.1 to 38.8)</td>
<td>15.4 (4.4 to 34.9)</td>
<td>8.2 (-11.1 to 27.6)</td>
<td>0.40</td>
<td>11.4 (-22.0 to 44.7)</td>
</tr>
<tr>
<td>25-26</td>
<td>17.8 (11.4 to 25.9)</td>
<td>7.9 (4.5 to 12.6)</td>
<td>-9.9 (-16.9 to -2.9)</td>
<td>0.005</td>
<td>-8.6 (-16.5 to -0.6)</td>
<td>0.035</td>
</tr>
<tr>
<td>27-31</td>
<td>105/1271</td>
<td>8.0 (6.6 to 9.7)</td>
<td>4.9 (3.7 to 6.4)</td>
<td>-3.2 (-4.9 to -1.4)</td>
<td>&lt;0.001</td>
<td>-2.7 (-4.5 to -0.9)</td>
</tr>
<tr>
<td>32-34</td>
<td>30/847</td>
<td>2.8 (1.5 to 4.7)</td>
<td>0.2 (0.0 to 1.3)</td>
<td>-2.6 (-3.2 to -1.9)</td>
<td>&lt;0.001</td>
<td>-3.3 (-5.9 to -0.7)</td>
</tr>
</tbody>
</table>

Percentages are weighted to account for differences in sampling process between gestational age groups.

* Risk differences were estimated with a binomial model with identity link.

† Adjusted for gestational age, sex, small for gestational age, and multiple pregnancy.

‡ Complete cases analysis. No survivors at 22-23 weeks in the nine regions participating in both EPIPAGE studies.

§ Results based on data using multiple imputation. Severe or moderate neuromotor or sensory disability: severe=cerebral palsy GMFCS levels 3-5 and/or bilateral deafness and/or bilateral blindness; moderate=cerebral palsy GMFCS level 2 and/or unilateral deafness and/or unilateral blindness.
In this French population based cohort of neonates born at 22-34 weeks' gestation in 2011, rates of survival without severe or moderate neuromotor and sensory disabilities at 2 years corrected age of 48.5%, 90.0%, and 97.5% were observed for children born at 22-26, 27-31, and 32-34 weeks' gestation, respectively. Only one child born at 22-
23 weeks’ gestation survived. After adjustment for changes in the baseline characteristics of infants over time, rates of survival and survival without severe or moderate neuromotor and sensory disabilities at 2 years corrected age increased between 1997 and 2011 for children born at 22-31 weeks’ gestation but no change was found for children born at 24 weeks’ gestation or earlier. Rates of cerebral palsy decreased by 3.3% between the two epochs, which was statistically significant, at both 24-31 and 32-34 weeks’ gestation. After excluding children with cerebral palsy, blindness, deafness, or severe congenital brain malformations, 50.2%, 40.7%, and 36.2% of children born at 24-26, 27-31, and 32-34 weeks’ gestation, respectively, had Ages and Stages Questionnaire (ASQ) scores below threshold and were considered at risk of developmental delay. Communication and personal-social domains were the domains most frequently scoring below threshold.

Strengths and limitations of this study
The strengths of the EPIPAGE-2 study include the population based cohort design, at a national level, with prospective enrolment of a large number of infants born not only extremely preterm but also very and moderately preterm, whose outcome has been infrequently reported. We used standardised definitions of outcomes following international recommendations, thus allowing comparison with other international cohorts. In addition, we obtained face to face assessments to diagnose cerebral palsy and we explored the full range of development with the ASQ to better understand profiles of development by gestational age group.

The main limitation of the study was the number of children lost to follow-up, although the follow-up rate was high in terms of the size of the cohort. Results from other studies suggest an excess of poorly performing children among those not evaluated because the parents of children from more disadvantaged families are more often non-responders. We also found a social bias in participation, with more families of a low socioeconomic status initially refusing participation or not responding at two years. We used multiple imputation to account for missing data. This did not modify the rate of cerebral palsy but showed a consistent increase across gestational age groups in the proportion of children with ASQ scores below threshold, similar to the impact of socioeconomic status on development seen in other studies. In addition, because of the number of doctors involved in the study, their ability to diagnose cerebral palsy might have varied. However, this was a pragmatic choice that means our results also reflect how cerebral palsy is diagnosed in routine practice. Milder forms of cerebral palsy may have been missed but most of the doctors were paediatricians involved in the routine follow-up of children born preterm, and a standardised questionnaire was used to minimise ambiguous answers. Finally, the lack of cognitive evaluation by trained psychologists may limit comparisons with other cohorts. We used the ASQ, a parent based developmental questionnaire, reported as useful to identify children at risk of having a developmental quotient less than 85, with a sensitivity of 87% and a specificity of 77%. However, the correlation between the ASQ score and a standardised, professionally administered developmental test score is higher in preterm children than term born children, increases with increasing age at assessment, and two years seems a reliable period to assess neurodevelopment with the ASQ. In addition, children born preterm with low scores on the ASQ at 2 years of age, but without neurodevelopmental impairment, have statistically lower Bayley Scales of Infant Development scores compared with children with ASQ scores above threshold, and, more recently, the predictive value of ASQ at 3 years for IQ at 5-6 years has been described. Nevertheless, assessing neurodevelopment at 2 years, compared with later school age outcomes, is challenging as a child’s development does not have a fixed trajectory and some children will recover from developmental delay while for others their deficit will become apparent as they grow. Children identified early using parental questionnaires might benefit from closer follow-up and a standardised evaluation with formal psychometric tests. Our data offer real life estimates, at a national level, of the number of children in each gestational age grouping who may need to be included in formal follow-up using parental questionnaires to assess development. As expected, parents who did not complete the questionnaire or completed the questionnaire outside the expected age range were of a lower socioeconomic status, and thus may need additional support when assessing development with a parental questionnaire. The decline in the rates of cerebral palsy that we observed is consistent with those of cerebral palsy registers describing a decreased prevalence of cerebral palsy over time, and a substantial reduction in the most severe forms, especially in very low and moderately low birthweight neonates. As for other cohorts based on gestational age, we did not find a reduction in the most severe forms (data not shown), but the number of children with severe cerebral palsy was too small to observe such a difference. Rates of sensory impairments were very low but reporting sensory outcomes at extremely low gestation is essential because impairment increases with age. In the EXPRESS cohort, the frequencies of blindness and visual impairment increased between 30 months’ corrected age and 6.5 years, with children born before 25 weeks’ gestation showing the highest risk of visual problems.

Comparison with other studies
The improvements in survival and neurodevelopmental outcomes that we observed may reflect advances in implementation of evidence based practices in obstetric and neonatal care. We observed an increase in the use of antenatal corticosteroids and surfactant, together with a decline in the postnatal
RESEARCH

use of steroids, associated with a decrease in severe neonatal morbidities. Our results provide additional evidence for the effectiveness of strategies adopted in the perinatal period, although the respective role of each strategy is unknown. However, in France, compared with countries with active resuscitation for perivable neonates, only one infant born at 22-23 weeks' gestation survived, and rates of survival and survival without neuromotor or sensory disabilities were poor for children born at 24 weeks' gestation, with no noticeable improvement between 1997 and 2011 in either practices or outcomes. As expected from the French recommendations, we have previously reported that intensive care was withheld or withdrawn in the delivery room for 92.6% of neonates born at 22-23 weeks' gestation, with provision of comfort care until death for those born alive. In The Netherlands, where perinatal care at extremely low gestation is comparable to that in France, the proportion of children with severe or moderate disabilities at 2 years was higher than those we report from France but included children with cognitive impairments. The impact of active treatment at 22-23 weeks' gestation on outcomes at 24 weeks' gestation and thereafter is a real question. One hypothesis is that if you provide active care at 22-23 weeks' gestation, outcomes at 24-26 weeks' gestation improve. Marked differences in hospital practices regarding the initiation of active treatment in infants born at 22, 23, or 24 weeks' gestation were observed in a sample of units in the USA, with hospital rates of active treatment accounting for nearly 80% of the between-hospital variation in survival without severe impairment among children born at 22 or 23 weeks, but this relation was attenuated among those born at 24 weeks. In another paper, the same group suggested that centres with higher rates of antenatal corticosteroids at 22-24 weeks had reduced rates of death and neurodevelopmental impairment among children born at higher gestational age. We report a 6.9% rate of cerebral palsy at 24-26 weeks' gestation, with similar proportions at 24 and 25 weeks' gestation and a statistically significant decrease at 26 weeks' gestation. Comparisons with other cohorts are difficult as rates were reported for 22-26 weeks' gestation and not by individual weeks of gestation. Reported rates of cerebral palsy in surviving infants born at 22-26 weeks' gestation vary from 7% in Sweden to 10% in Australia and 14% in England. Further research is needed to better understand the role of different strategies of care on outcomes of extremely premature neonates and the influence of key practices for perivable births that might improve outcomes in more mature neonates.

The proportion of children with ASQ scores below threshold may appear high in our cohort. On the basis of ASQ reference values, 12% to 17% of children from the general population are considered to need further evaluation in at least one developmental domain at 2 years. Higher proportions have been found at the same age in children born preterm: 41% of those born before 28 weeks' gestation in a Dutch hospital based cohort and 46% in a French regional based cohort of children born at less than 32 weeks' gestation. As a screening instrument, ASQ identifies more children at risk of developmental delay than those with a diagnosis based on professionally administered psychometric tests. The risk of potential over-identification has been widely debated, but children with suspected delay may represent a group at risk for future academic difficulties and who could require dedicated support systems. In each gestational age group, communication was the domain most frequently scoring below threshold, with proportions that were still 17.8% at 32-34 weeks' gestation. Delay in language development, together with poorer social-emotional competence, was also recently described in an Australian cohort of children born between 32 and 36 weeks, and stability of poor language performance from 20 months to 8 years of age has been shown to be greater for preterm children than for term children. Given the high prevalence of births after 31 weeks' gestation, early identification of children at risk of later difficulties to provide targeted interventions may have a broad impact on learning disabilities. We have shown that parents' socioeconomic status and small for gestational age were the main factors associated with ASQ scores below threshold, and these should be considered when planning follow-up. Few interventions have been shown to have a long-term impact on cognitive outcome, but the impact on parents' wellbeing merits consideration. Compared with children born at 27-31 or 32-34 weeks' gestation, a higher proportion of children born at 24-26 weeks' gestation showed ASQ scores below threshold in the gross motor domain. Most children failed the most complex gross motor items: "jump with both feet" ("not yet"=93%) and "kicking a ball" ("not yet" or "sometimes"=78%) (data not shown). It is likely that some of these children will be identified later as children with developmental coordination disorders.

Context of the study
This study evaluated outcomes at 2 years corrected age in a large group of preterm babies, born at 22-34 weeks' gestation. French practices do not differ greatly from those in many other European countries, and our results may be applicable elsewhere. The proportion of infants at risk of developmental delay was high, even for those born at 32-34 weeks' gestation, which raises the question of including these children in follow-up. This might have a great implication in terms of cost and the size of the workforce required, but individualising follow-up according to risk factors other than gestational age, together with the use of tools easily used in community services, should be considered. Parental questionnaires are increasingly popular: they can be used at the community level to identify children needing further assessment, and decrease the cost of medical expenditure. Further follow-up of our study sample is in progress and will enable us to examine whether ASQ scores below threshold are predictors of later difficulties at 5 years.
The EPIPAGE-2 cohort study provides an extensive description of practices around birth at extremely low gestation, and in a country where active perinatal intervention is not currently recommended. For infants born at extremely low gestation, a consistent concern in the literature is that increased survival may come at the expense of increased long term sequelae, although recent studies counter this notion. A 2010 European survey exploring national guidelines of resuscitation for infants born at 22-25 weeks of gestation, in a country where active perinatal intervention for infants born before 24 weeks' gestation, with provision of comfort care until death for those born alive. Our results invite questioning perinatal strategies in France, and in countries with similar recommendations. However, improving outcomes at extremely low gestational age requires a complex change in philosophy of care and close cooperation not only between obstetricians and neonatologists, but also developmental specialists, parent associations, and policy makers. Efficient regionalised referral systems and antenatal steroids are usually the main focus of intervention advocated to improve outcome, but countries reporting better outcomes also differ in quality of family centred care and the organisation of follow-up.

Conclusion

In this national population based cohort of preterm neonates, we showed improvements in survival at 2 years without neuromotor disabilities in each gestational age group between 1997 and 2011. There was a statistically important decrease in the rate of cerebral palsy but the risk of developmental delay was high, even in children born moderately preterm. Parental questionnaires may represent a promising alternative for early identification of children at risk of later difficulties.

AUTHOR AFFILIATIONS

*Obstetric and Perinatal Epidemiology Team, Epidemiology and Biostatistics Sorbonne Paris Cité Research Center (U1135), INSERM, Paris, France; Paris Descartes University, Paris, France
*CHU Lille, Department of Neonatal Medicine, Jeanne de Flandre Hospital, F-59000 Lille, France
*INSERM UMR 1027, Université Toulouse III Paul Sabatier, Toulouse, France
*Biosociétés and Medical Information Department, AP-HP Saint-Louis Hospital, Paris, France
*École des Hautes Études en Santé Publique (EHESP), Rennes, France
*Maternité Port-Royal, Université Paris Descartes; Groupe Hospitalier Cochin Broca Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, DHU Risques et Grossesse, Paris, France
*Department of Neonatal Pediatrics, Intensive care, and Neuropediatrics, Rouen University Hospital, Rouen, France
*Research Unit U1245, Institute for Research and Innovation in Biomedicine, Rouen, France
*Clinical Research Unit, Center for Clinical Investigation P1419, Cochin Broca Hôtel-Dieu Hospital, Paris, France

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: This study was approved by the National Data Protection Authority (CNIL no. 91 1009) and by appropriate ethics committees (Consultative Committee on the Treatment of Data on Personal Health for Research Purposes - reference no. T0 626, Committee for the Protection of People Participating in Biomedical Research - reference CPP SC 287-3).

Data sharing: The EPIPAGE studies are subject to a data sharing agreement and a data sharing plan is available on request. The EPIPAGE studies are subject to a data sharing agreement and a data sharing plan is available on request.
TRANSPARENCY: The manuscript's guarantor (VP) affirms that the manuscript is honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.


Dilemmas and management. Part 1. Outcome of infants born before 24 weeks of postmenstrual age, and definition of a gray zone]. Dilemmas and management. Part 1. Outcome of infants born before 24 weeks of postmenstrual age, and definition of a gray zone].


Appendix: Supplementary materials